当前位置:循环首页>正文

[GWICC2009]ACC主席Alfred A. Bove教授谈远程医疗防治心衰

作者:国际循环网   日期:2009/11/6 9:32:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

International Circulation: You talked about the key clinical trials from ACC 2009. What do you think are the 2 most influential trials this year? What changes in clinical practice do you foresee will happen due to these trial results?

International Circulation: You talked about the key clinical trials from ACC 2009. What do you think are the 2 most influential trials this year? What changes in clinical practice do you foresee will happen due to these trial results?

Alfred Bove:  One of the most important trials from ACC was the SYNTAX trial.  It was a trial compareing surgery to intervention in patients that needed some kind of revascularization.   The outcome of the trial showed no difference between surgery and PCI.  Among the two different communities, the intervention community thought it was wrong and, of course, the surgical community thought it was correct.   Dr. Turco earlier today made a good review of the subsets of SYNTAX.  There are places where either therapy would work the same but there are clearly some patients where surgery is better and some patients where PCI is better.  Like every other trial when you have a large population of patients, the average may tell you one thing but we don’t see patients as the average. We see each patient as an individual.  When you sort out the different kinds of patients, it is clear that there are choices that favor PCI in some cases and others that favor surgery.  That is one of the important trials that I think is going to make a lot of changes in the way we approach patients and in our thinking regarding how we manage patients with coronary artery disease in need of revascularization.  That is why I think the SYNTAX trial is important.
The other trial that I mentioned was called RELY which is also a very important trial.  We have been treating atrial fibrillation for many years with Warfarin.  It is the only drug we have to reduce the risk of stroke.  We have aspirin but aspirin is not quite as good.  Warfarin is the drug everyone uses and have been part of clinical trials for years. It is believed to be the drug needed to reduce the risk of stroke in patients through a spectrum of ages from around 60 up to the 70s and 80s.  People are looking at different alternatives to produce anticoagulation rather than Factor VII inhibition. Medications that seem to have promise are the thrombin inhibitor drugs.  The first one was ximelagatran, which showed very nicely that it could match Warfarin in terms of the reduction of the risk of stroke.  However, it turned out to have a very serious liver side effect and was never approved for use.  Therefore, everyone began to work on changing the molecule so that it would be safer to the liver but still provide the benefit of anticoagulation.  Now we have dabigatran, which was presented in the RELY trial. It shows an extremely good promise to be an alternative to Warfarin in atrial fibrillation.  Dabigatran, when it was examined at two doses, showed a slightly better outcome than Warfarin both in terms of preventing stroke and reducing the number of bleeding events.  The major complication with blood thinners is bleeding. It looks like Dabigatran is one of the drugs that could provide the anticoagulation benefit without a great risk of bleeding.  Those two trials among others are having an appreciable impact in clinical practice and influencing how physicians make decisions. 

[1]  [2]  [3]  下一页

版面编辑:李雅峰



心力衰竭长城会Alfred A. Bove教授

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530